Skip to main content
Terug
JAZZ logo

Jazz Pharmaceuticals plc

Datakwaliteit: 100%
JAZZ
NASDAQ Healthcare Biotechnology
€ 185,01
▲ € 2,69 (1,48%)
Marktkapitalisatie: 11,39B
Dagbereik
€ 180,68 € 185,07
52-Weeksbereik
€ 95,49 € 198,00
Volume
1.476.713
50D / 200D Gem.
€ 173,53 / € 144,04
Vorige Slotkoers
€ 182,32

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -32,0 0,3
P/B 2,6 2,9
ROE % -8,5 3,7
Net Margin % -8,4 3,8
Rev Growth 5Y % 8,4 10,0
D/E 1,3 0,2

Koersdoel Analisten

Hold
€ 207,86 +12.4%
Low: € 170,00 High: € 235,00
Forward K/W
7,6
Forward WPA
€ 23,93
WPA Groei (sch.)
+0,0%
Omzet Sch.
4,4 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 31,98
€ 30,75 – € 33,42
6 B 2
FY2029 € 30,88
€ 29,69 – € 32,27
5,8 B 2
FY2028 € 26,64
€ 19,61 – € 32,84
5,2 B 4

Belangrijkste Punten

Revenue grew 8,37% annually over 5 years — modest growth
Earnings declined -163,58% over the past year
Generating 1,30B in free cash flow
PEG of 0,18 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 3,49%
Capital efficient — spends only 1,38% of revenue on capex

Groei

Revenue Growth (5Y)
8,37%
Revenue (1Y)4,88%
Earnings (1Y)-163,58%
FCF Growth (3Y)10,20%

Kwaliteit

Return on Equity
-8,47%
ROIC1,73%
Net Margin-8,35%
Op. Margin5,26%

Veiligheid

Debt / Equity
1,26
Current Ratio1,86
Interest Coverage1,15

Waardering

P/E Ratio
-31,98
P/B Ratio2,64
EV/EBITDA68,72
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4,88% Revenue Growth (3Y) 5,50%
Earnings Growth (1Y) -163,58% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8,37% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4,27B Net Income (TTM) -356,15M
ROE -8,47% ROA -3,05%
Gross Margin 88,21% Operating Margin 5,26%
Net Margin -8,35% Free Cash Flow (TTM) 1,30B
ROIC 1,73% FCF Growth (3Y) 10,20%
Safety
Debt / Equity 1,26 Current Ratio 1,86
Interest Coverage 1,15 Dividend Yield 0,00%
Valuation
P/E Ratio -31,98 P/B Ratio 2,64
P/S Ratio 2,67 PEG Ratio 0,18
EV/EBITDA 68,72 Dividend Yield 0,00%
Market Cap 11,39B Enterprise Value 15,42B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,27B 4,07B 3,83B 3,66B 3,09B
Net Income -356,15M 560,12M 414,83M -224,06M -328,95M
EPS (Diluted) -5,84 8,65 6,10 -3,58 -5,51
Gross Profit 3,76B 3,62B 3,40B 3,12B 2,65B
Operating Income 224,42M 716,63M 578,58M -65,53M 170,28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 11,66B 12,01B 11,39B 10,84B 12,30B
Total Liabilities 7,34B 7,92B 7,66B 7,75B 8,33B
Shareholders' Equity 4,32B 4,09B 3,74B 3,09B 3,97B
Total Debt 5,42B 6,16B 5,79B 5,81B 6,15B
Cash & Equivalents 1,39B 2,41B 1,51B 881,48M 591,45M
Current Assets 4,17B 4,63B 3,44B 2,61B 2,61B
Current Liabilities 2,24B 1,04B 1,54B 933,19M 809,30M